{"name": "Labopharm",
 "permalink": "labopharm",
 "crunchbase_url": "http://www.crunchbase.com/company/labopharm",
 "homepage_url": "http://www.labopharm.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "medinfo@labopharm.com",
 "phone_number": "(450) 686-1017 ",
 "description": "",
 "created_at": "Thu Aug 18 04:22:24 UTC 2011",
 "updated_at": "Thu Aug 18 04:22:22 UTC 2011",
 "overview": "\u003Cp\u003ELabopharm Inc. is an international, specialty pharmaceutical company focused on optimizing the performance of existing drugs by incorporating its advanced controlled-release technologies. The Company\u00e2\u20ac\u2122s lead product, a once-daily formulation of the analgesic tramadol, is being commercialized internationally and it focuses to pursue additional launches in markets around the world. Its second product, OLEPTRO, a once-daily formulation of trazodone (a serotonin antagonist reuptake inhibitor) for the treatment of major depressive disorder (MDD) has received regulatory approval from the United States Food and Drug Administration (FDA) and is in the process of finalizing the commercialization plan for its product. It is also developing a series of abuse- and misuse-deterrent products based on its Contramid-based technology platform. In addition, it has other products in development utilizing its Contramid or its polymeric nano-delivery system (PNDS) technologies. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       94],
      "assets/images/resized/0014/9976/149976v1-max-150x150.png"],
     [[156,
       98],
      "assets/images/resized/0014/9976/149976v1-max-250x250.png"],
     [[156,
       98],
      "assets/images/resized/0014/9976/149976v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Mark",
      "last_name": "D'Souza",
      "permalink": "mark-dsouza",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Sylvain",
      "last_name": "Gu\u00c3\u00a9nette",
      "permalink": "sylvain-gunette",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition":
  {"price_amount": null,
   "price_currency_code": "USD",
   "term_code": "cash_and_stock",
   "source_url": "http://www.thepressreleasewire.com/client/paladin_labs/releaseen.jsp?year=2011\u0026actionFor=1487097\u0026releaseSeq=0",
   "source_description": "Labopharm Inc. Enters Into an Agreement to Be Acquired by Paladin Labs Inc. ",
   "acquired_year": 2011,
   "acquired_month": 8,
   "acquired_day": 17,
   "acquiring_company":
    {"name": "Paladin Labs",
     "permalink": "paladin-labs",
     "image":
      {"available_sizes":
        [[[150,
           29],
          "assets/images/resized/0006/0661/60661v1-max-150x150.png"],
         [[166,
           33],
          "assets/images/resized/0006/0661/60661v1-max-250x250.png"],
         [[166,
           33],
          "assets/images/resized/0006/0661/60661v1-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "480 Armand-Frappier Blvd. ",
    "address2": "Laval",
    "zip_code": "H7V 4B4 ",
    "city": "Qu\u00c3\u00a9bec",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}